Clinical Trials
647
77 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
53
8.2%
Completed
361
55.8%
Enrolling By Invitation
3
0.5%
Not yet recruiting
21
3.3%
Recruiting
120
18.6%
Suspended
3
0.5%
Terminated
48
7.4%
Unknown
4
0.6%
Withdrawn
34
5.3%
No approval data available
- Ohio State University has launched Buckeye BioLaunch, a new AI-enabled initiative to accelerate therapeutic discovery, development, and commercialization across the full drug development continuum. - The initiative will support 10 to 20 AI-driven screening projects annually, leveraging clinical and genomic datasets from Ohio State Genomic Health combined with expertise from the Colleges of Medicine and Pharmacy. - Progress will be measured through composition-of-matter patents, technical development milestones, licenses, startup formation, and clinical trials, with the goal of producing new medicines every five to 10 years. - The effort aims to drive biotech growth, job creation, and economic development in central Ohio while positioning the university as a national force in therapeutic innovation.
- A Phase 1 clinical trial for the first-ever leishmaniasis vaccine is set to begin in the coming months, testing safety in healthy volunteers across Kenya, Brazil, and potentially the United States. - The live attenuated vaccine, developed at Ohio State University using CRISPR gene-editing to delete the centrin gene from Leishmania major, was 100% effective in animal studies. - Up to 1 million new cases of cutaneous leishmaniasis are diagnosed annually worldwide, with approximately 1 billion people at risk across 99 endemic territories and countries, now including the U.S. - Researchers estimate the vaccine would cost less than $5 per dose, compared to $100–$200 for current treatments requiring weeks of daily injections with significant side effects.
- Akamis Bio's NG-350A combined with chemoradiotherapy achieved a 50% composite response rate in the first 10 patients with mismatch repair-proficient locally advanced rectal cancer, doubling the expected 25% rate from standard treatment alone. - The Phase 1b FORTRESS study demonstrated no serious adverse events related to NG-350A, with the oncolytic immunotherapy designed to drive intratumoral expression of a CD40 agonist antibody. - Results could enable more patients to pursue organ-preserving "watch-and-wait" protocols instead of life-altering rectal surgery, particularly important as colorectal cancer becomes the leading cause of cancer death in patients under 50. - The encouraging preliminary data provides clinical proof of concept for NG-350A's potential to advance the standard of care for the approximately 30,000 patients diagnosed annually with this condition in the US.
- The FDA breakthrough device program has maintained a consistent pace in fiscal year 2026, awarding 42 designations in the first quarter, tracking toward 168 total designations for the year. - Since its inception, the program has granted breakthrough status to 1,246 devices, with 185 receiving marketing authorization and cardiovascular, neurology, and orthopedics leading in designations. - Bipartisan congressional bills propose automatic four-year Medicare coverage for breakthrough devices, sparking debate among health policy researchers about potential low-value spending. - Health policy experts express concerns that regulatory flexibilities for breakthrough devices may lead to market entry with less rigorous evidence supporting their clinical effectiveness.
- DNA Nanobots secured $3.5 million in funding from a family office to advance its self-assembling nanoscale therapeutics platform over the next 18 months. - The company utilizes DNA origami technology to engineer nanobots that deliver therapeutic payloads directly to diseased cells with unprecedented specificity while minimizing systemic toxicity. - Funding will support pre-clinical studies, production capabilities expansion, IP portfolio development, and strategic hiring to prepare for IND-enabling studies. - The company is seeking an additional $1.5 million to complete its $5 million seed round, which will enable initiation of first-in-human clinical trials.
- The Ohio State University's Center for Psychedelic Drug Research and Education received a $400,000 grant to train over 127,000 Ohio healthcare professionals in psychedelic harm reduction and crisis response. - The P.E.A.C.E. program addresses rising psychedelic use, which increased from 2.7% to 3.6% of Americans aged 12 and older between 2021 and 2024 according to national survey data. - The initiative collaborates with MAPS to provide specialized training modules for emergency responders, law enforcement, and behavioral health professionals on psychedelic crisis recognition and response. - Training seminars will be offered at no cost in January, March, and July 2026 to ensure Ohio's workforce has evidence-based tools for managing psychedelic-related emergencies.
- IIT Madras researchers collaborated with Ohio State University to develop PURE, an AI framework that uses reinforcement learning to generate drug-like molecules that are easier to synthesize in laboratories. - The framework promises to significantly reduce early-stage drug development timelines, addressing the current billion-dollar, decade-long process that plagues pharmaceutical research. - PURE stands apart from existing AI tools by avoiding rigid scoring mechanisms and instead learning how molecules transform through synthesis steps, similar to how a chemist would reason. - The framework shows potential beyond drug discovery, offering a foundation for accelerated discovery of new materials and addressing drug resistance in cancer and infectious diseases.
- Neucore Bio secured a $350,000 STTR Phase I grant from NIH's NCATS to develop an exosome-based RNA therapy targeting Charcot-Marie-Tooth Disease Type 1A. - The company's proprietary FiXE™ platform aims to deliver microRNA constructs to Schwann cells to regulate PMP22 gene overexpression in this genetic neuromuscular disorder. - CMT1A currently has no approved therapies, making this non-viral delivery approach a potentially significant advancement for patients with this progressively debilitating condition. - The research partnership with Ohio State University's Gene Therapy Institute will focus on optimizing engineered extracellular vesicles for targeted therapeutic delivery.
